Investigating the P53-dependent anti-cancer effect of ibutamoren in human cancer cell lines.
This study investigated whether ibutamoren (IBU) — a compound known primarily as a growth hormone secretagogue — might also act as an inhibitor of the MDM2-p53 interaction, a pathway dysregulated in roughly half of human cancers. MDM2 normally tags the tumour suppressor p53 for degradation; blocking this interaction is a recognized anticancer strategy. The researchers first used in silico molecular modelling to predict that IBU binds favorably to the p53-binding pocket of MDM2 and exhibits a low estimated IC50 for MDM2 inhibition. They then tested IBU on immortalized human cancer cell lines in vitro, finding reduced cell viability in lines with an intact, functional MDM2-p53 pathway but not in lines carrying damaging mutations in this pathway. RT-qPCR analysis supported this pattern, showing differential expression of two p53 target genes in wild-type but not mutant cell lines after IBU treatment. Key limitations include exclusive reliance on cell-line models (no animal or human data), use of immortalized rather than primary cells, and the preliminary, exploratory nature of the work. The authors conclude that IBU shows early-stage anticancer activity potentially mediated through the MDM2-p53 axis and warrants further mechanistic investigation.
Why this grade: All experimental findings are derived solely from computational modelling and immortalized human cancer cell lines, with no animal models or human subjects involved.
The MDM2-p53 pathway plays a pivotal role in regulating cell cycle and apoptosis, with its dysfunction contributing to approximately 50% of human malignancies. MDM2, an E3 ubiquitin ligase, targets the tumour suppressor p53 for degradation, thereby promoting uncontrolled cell growth in cancers. Inhibiting the MDM2-p53 interaction represents a promising therapeutic strategy for reactivating p53's tumour-suppressive functions. This study explored the potential of ibutamoren (IBU) as a novel inhibitor of MDM2. In silico analyses utilizing molecular modelling revealed that IBU has a low IC 50 for MDM2 inhibition and favourably binds to the p53-binding pocket of MDM2. In vitro experiments demonstrated that IBU treatment reduced the viability of immortalized cancer cell lines with a functional MDM2-p53 pathway but not in cell lines where this pathway harboured damaging mutations. This trend was further supported by RT-qPCR analysis, which showed differential expression of two p53 target genes upon IBU treatment in cell lines with wild MDM2-p53 pathways but not in those harbouring damaging mutations. These findings provide preliminary evidence supporting IBU's anticancer activity, plausibly through the MDM2-p53 pathway, and suggest that further studies are warranted to explore its mechanism of action and potential development as a lead compound in oncology research.
Educational summary of published research — not medical advice. Full text is shown only where licensing permits.